In a blast from the past, COVID-19 vaccine developer Moderna (NASDAQ: MRNA) just made headlines in 2026. Shares jumped up ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

WASHINGTON — The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients — revving up their immune systems to help fight tumors. People with advanced lung or skin ...

Penny stocks attract speculative investors looking for high-risk/high-reward opportunities. That means looking for companies with disruptive technologies, that are part of an emerging trend, or ones ...

"One guy I went to high school with helped plan the Charlottesville Rally where the woman was killed, and he did time for his ...

This ASX heavyweight has potential to deliver superior returns but is more volatile. The post Is CSL or Sonic Healthcare the ...

Vice President JD Vance on Thursday said the Insurrection Act wouldn’t be needed “right now” in Minneapolis after meeting ...

Infant protection against respiratory syncytial virus (RSV) by maternal RSV vaccination or receipt of RSV monoclonal antibody ...

We enlisted a dozen testers to put 18 laptops through rigorous testing. These are the best laptops based on performance, ...

Top pharma stocks by Quant Ratings: see Strong Buy/Buy picks across PJP/XPH/PPH—plus why Moderna surged on new cancer-trial ...

The Trump administration has rolled back decades-old guidance recommending routine childhood vaccination against influenza and three other infectious diseases, saying their use should instead be ...

Nirsevimab may offer infants stronger protection against severe respiratory syncytial virus than maternal vaccination, ...